

Konstantin Tachkov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4292579/publications.pdf>

Version: 2024-02-01

37
papers

369
citations

1040056

9
h-index

839539

18
g-index

39
all docs

39
docs citations

39
times ranked

569
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Healthcare Expenditures in Bulgaria. <i>Healthcare (Switzerland)</i> , 2022, 10, 274.	2.0	1
2	Impact of Polypharmacy, Drug-Related Problems, and Potentially Inappropriate Medications in Geriatric Patients and Its Implications for Bulgariaâ€™ Narrative Review and Meta-Analysis. <i>Frontiers in Public Health</i> , 2022, 10, 743138.	2.7	10
3	Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 905-913.	1.4	7
4	Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. <i>Pharmaceuticals</i> , 2021, 14, 64.	3.8	8
5	A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care. <i>Frontiers in Endocrinology</i> , 2021, 12, 636959.	3.5	12
6	Is There a Symmetry in Disease Control and Quality of Life of Patients with Rheumatoid Arthritis Treated with Biological Therapy?. <i>Symmetry</i> , 2021, 13, 538.	2.2	3
7	The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. <i>Frontiers in Public Health</i> , 2021, 9, 671961.	2.7	22
8	Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria. <i>Healthcare (Switzerland)</i> , 2021, 9, 697.	2.0	0
9	Pharmacotherapeutic Patterns and Patientsâ€™ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria â€“ A Pilot Comparative Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 695181.	3.5	1
10	Review of medicine utilization for Parkinsonâ€™s disease management: the Bulgarian perspective. <i>Journal of Public Health Research</i> , 2021, , .	1.2	0
11	Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. <i>BioMed Research International</i> , 2021, 2021, 1-16.	1.9	7
12	Cost-effectiveness of in vitro fertilization and controlled ovarian hyperstimulation before and after the COVID-19 outbreak. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 1820-1826.	1.3	1
13	Cardiovascular co-morbidity in patients with COPD in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2020, 34, 918-924.	1.3	1
14	Fixed dose drug combinations â€“ are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 1-26.	1.4	47
15	Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria. <i>PLoS ONE</i> , 2020, 15, e0232815.	2.5	21
16	The Expiry of Humiraâ€™ Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. <i>Frontiers in Pharmacology</i> , 2020, 11, 591134.	3.5	44
17	Micro and macro analysis on the burden of COPD hospitalizations on the Bulgarian healthcare system. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 1-11.	1.3	2
18	Improved quality of diabetes control reduces complication costs in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 814-820.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Chronic obstructive pulmonary disease exacerbations and progression in relation to ambient air pollutants exposure. <i>Journal of Thoracic Disease</i> , 2019, 11, 2490-2497.	1.4	6
20	Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 671-682.	1.3	56
21	Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria. <i>Frontiers in Public Health</i> , 2019, 7, 70.	2.7	2
22	Cost-of-illness studies in nine Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2019, 20, 155-172.	2.8	23
23	Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 733-742.	1.4	6
24	Modeling the Pharmacotherapy Cost and Outcomes of Primary Open-Angle Glaucoma With Dry Eye. <i>Frontiers in Public Health</i> , 2019, 7, 363.	2.7	5
25	Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2237-2255.	1.8	38
26	BUDGET IMPACT ANALYSIS OF INHIBITOR HAEMOPHILIA A THERAPY WITH BYPASSING AGENTS. <i>Journal of IMAB</i> , 2019, 25, 2511-2515.	0.1	0
27	Orphan medicinal productsâ€™ access to the Bulgarian pharmaceutical market â€“ challenges and obstacles. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 95-104.	0.8	5
28	Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines. <i>Frontiers in Pharmacology</i> , 2018, 9, 794.	3.5	22
29	A one-way, static Markov model estimating the social and economic burden of chronic obstructive pulmonary disease in Bulgaria for patients who smoke or don't. <i>Biomedical Research (Aligarh, India)</i> , 2018, 29, .	0.1	1
30	Cost-effectiveness of different types of COH protocols for in vitro fertilization at national level. <i>Biotechnology and Biotechnological Equipment</i> , 2017, 31, 206-214.	1.3	2
31	Evaluation of the economic and social burden of chronic obstructive pulmonary disease (COPD). <i>Biotechnology and Biotechnological Equipment</i> , 2017, , 1-7.	1.3	6
32	Generics and fixed-dose combinations in cardiology: satisfaction analysis of pharmacists and cardiologists. <i>Biotechnology and Biotechnological Equipment</i> , 2016, 30, 204-211.	1.3	1
33	Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting. <i>Biotechnology and Biotechnological Equipment</i> , 2014, 28, 366-371.	1.3	3
34	Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment. <i>Biotechnology and Biotechnological Equipment</i> , 2014, 28, 576-582.	1.3	0
35	Financial Analysis of the Access to Pharmacotherapy for Rare Diseases in Bulgaria. <i>Modern Economy</i> , 2014, 05, 461-467.	0.5	2
36	Modelling the Financial Framework of the Pharmacotherapy Cost of Rare Diseases with Orphan Medicinesâ€™Part II. <i>Modern Economy</i> , 2014, 05, 499-505.	0.5	2

#	ARTICLE	IF	CITATIONS
37	Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies. <i>Rheumatology International</i> , 0, , .	3.0	0